It is well documented that the mean age at diagnosis of ovarian cancer among mutation carriers is lower than among unselected patients, and that the prevalence of BRCA1 mutations decline with increasing age at diagnosis (Risch et al, 2001). This evidence concerns the gene BRCA1 and ovarian cancer.